CYCN · As filed with the SEC
Korsana Biosciences balance sheet, by fiscal year
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 3,240,000 | 3,232,000 | 7,571,000 | 13,382,000 | 53,961,000 | 54,395,000 | 94,895,000 | — |
| Accounts receivable | 1,000,000 | 556,000 | 0 | 96,000 | 100,000 | — | — | — |
| Related party accounts receivable | — | — | — | — | 0 | 127,000 | 1,474,000 | — |
| Prepaid expenses | 384,000 | 421,000 | 442,000 | 805,000 | 928,000 | 816,000 | 1,966,000 | 867,000 |
| Other current assets | 11,000 | 16,000 | 11,000 | 537,000 | 468,000 | 3,163,000 | 2,862,000 | 12,000 |
| Total current assets | 4,635,000 | 4,225,000 | 8,024,000 | 14,820,000 | 55,457,000 | 58,501,000 | 101,197,000 | 879,000 |
| Restricted cash, net of current portion | — | — | — | — | 0 | 3,837,000 | 4,991,000 | — |
| Property and equipment, net | — | — | — | 0 | 65,000 | 6,865,000 | 11,613,000 | 6,497,000 |
| Operating lease right-of-use asset | — | — | 0 | 1,218,000 | 1,402,000 | 43,402,000 | 68,137,000 | — |
| Other investment | 5,350,000 | 5,350,000 | 5,350,000 | — | — | — | — | — |
| Other assets | — | — | 0 | 2,041,000 | 2,407,000 | 2,773,000 | 540,000 | 25,000 |
| Total assets | 9,985,000 | 9,575,000 | 13,374,000 | 18,079,000 | 59,331,000 | 115,378,000 | 186,478,000 | 7,401,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 508,000 | 390,000 | 1,198,000 | 2,970,000 | 1,828,000 | 1,149,000 | 3,230,000 | 2,781,000 |
| Related party accounts payable | — | — | — | — | 0 | 286,000 | 81,000 | — |
| Accrued research and development costs | 198,000 | 52,000 | 90,000 | 2,275,000 | 6,353,000 | 1,421,000 | 2,198,000 | 5,261,000 |
| Accrued expenses and other current liabilities | 194,000 | 283,000 | 798,000 | 2,382,000 | 2,904,000 | 7,294,000 | 9,320,000 | 9,804,000 |
| Short-term note payable | — | — | — | — | 0 | 3,509,000 | — | — |
| Current portion of operating lease liabilities | — | — | — | — | 0 | 3,293,000 | 3,420,000 | — |
| Total current liabilities | 900,000 | 725,000 | 2,086,000 | 7,627,000 | 11,085,000 | 16,952,000 | 18,249,000 | 17,846,000 |
| Operating lease liabilities, net of current portion | — | — | — | — | 0 | 38,933,000 | 70,500,000 | — |
| Commitments and contingencies (Note 6) | 0 | 0 | 0 | 0 | — | — | — | — |
| Stockholders' equity | ||||||||
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | — | — | — | — | — |
| Common stock, no par value, 400,000,000 shares authorized at December 31, 2025 and 2024; 3,925,314 and 2,710,096 shares issued at December 31, 2025 and 2024, respectively; 3,821,236 and 2,545,922 shares outstanding at December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Paid-in capital | 280,105,000 | 276,342,000 | 275,717,000 | 269,626,000 | 263,345,000 | 222,949,000 | 183,376,000 | — |
| Accumulated deficit | (271,020,000) | (267,492,000) | (264,417,000) | (259,154,000) | (215,076,000) | (163,429,000) | (85,627,000) | — |
| Net parent investment | — | — | — | — | — | — | — | (10,445,000) |
| Accumulated other comprehensive loss | — | 0 | (12,000) | (20,000) | (23,000) | (27,000) | (20,000) | — |
| Total stockholders' equity | 9,085,000 | 8,850,000 | 11,288,000 | 10,452,000 | 48,246,000 | 59,493,000 | 97,729,000 | (10,445,000) |
| Total liabilities and stockholders' equity | 9,985,000 | 9,575,000 | 13,374,000 | 18,079,000 | 59,331,000 | 115,378,000 | 186,478,000 | 7,401,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.